文献速递临床试验与 GCP流行病学与生物统计

立体定向放疗与海马保护全脑放疗治疗脑转移瘤的随机临床试验

Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

这项3期开放标签随机临床试验在美国4个中心纳入196例5至20个脑转移瘤且未接受过脑部放疗的患者,比较立体定向放疗与海马保护全脑放疗对患者报告症状严重程度及日常功能干扰的影响。结果显示,立体定向放疗组6个月内加权复合MD安德森症状量表-脑肿瘤评分从2.69降至2.37(平均变化-0.32),海马保护全脑放疗组从2.29升至3.03(平均变化0.74),组间平均差异为-1.06(95%CI,-1.54至-0.58;P<.001)。

要点

  • 在5至20个脑转移瘤患者中,立体定向放疗较海马保护全脑放疗改善症状严重程度及日常功能干扰。
  • 6个月内加权复合MD安德森症状量表-脑肿瘤评分平均差异为-1.06(95%CI,-1.54至-0.58;P<.001)。
  • 立体定向放疗组12例(12%)和海马保护全脑放疗组13例(13%)发生相关3-5级不良事件。

核心结论

  • 在5至20个脑转移瘤患者中,这些发现支持立体定向放疗优于海马保护全脑放疗,以改善症状及日常功能干扰,这是生活质量的关键组成部分。

研究设计与样本

  • 3期开放标签随机临床试验,在美国4个中心开展。
  • 纳入5至20个脑转移瘤且既往未接受脑部定向放疗的患者。
  • 入组时间为2017年4月11日至2024年5月17日,最终随访日期为2025年3月18日。
  • 共随机分配196例患者,平均年龄61岁,129例(66%)为女性,176例(90%)为白人,脑转移瘤中位数为14个(IQR,11-18),49例(25%)既往接受过神经外科切除。
  • 83例(42%)完成了6个月评估。

主要发现

  • 主要结局为基线至6个月随访期间加权复合MD安德森症状量表-脑肿瘤评分的平均变化。
  • 立体定向放疗组评分从2.69降至2.37(平均变化-0.32),海马保护全脑放疗组从2.29升至3.03(平均变化0.74)。
  • 组间平均差异为-1.06(95%CI,-1.54至-0.58;P<.001)。
  • 立体定向放疗组12例(12%)发生相关3-5级不良事件,海马保护全脑放疗组13例(13%)发生相关3-5级不良事件。
  • 1-3级疲乏最常见,立体定向放疗组27例(28%),海马保护全脑放疗组43例(44%)。

关键数值与推荐

  • MD安德森症状量表-脑肿瘤工具评分范围为0-10分,评分变化范围为-10至10分,-10代表最佳。
  • 临床有意义的变化值定义为0.98。

临床怎么用

  • 作者认为,在5至20个脑转移瘤患者中,这些发现支持立体定向放疗优于海马保护全脑放疗,以改善症状及日常功能干扰。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Brain metastases are common in patients with cancer, and radiation is often used for management. Among patients with more than 4 brain metastases, the effects of stereotactic radiation targeting only individual tumors, compared with whole brain radiation with hippocampal avoidance, which radiates both tumors and normal brain, remain unknown. OBJECTIVE: To determine whether stereotactic radiation improves symptom severity and interference with daily functioning, compared with whole brain radiation with hippocampal avoidance. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, open-label, randomized clinical trial conducted at 4 United States-based centers. Eligible patients had 5 to 20 brain metastases and no prior brain-directed radiation. Enrollment occurred between April 11, 2017, and May 17, 2024 (final follow-up, March 18, 2025). INTERVENTION: Stereotactic radiation, compared with whole brain radiation with hippocampal avoidance. MAIN OUTCOMES AND MEASURES: Mean weighted patient-reported symptom severity and interference score change over 6 months postbaseline relative to baseline using the MD Anderson Symptom Inventory-Brain Tumor instrument (scale, 0-10; score change range, -10 to 10; -10 = best). A clinically meaningful Δ was defined as 0.98. RESULTS: Of 196 randomized patients (mean age, 61 years; 129 [66%] female; 176 [90%] White; median number of brain metastases, 14 [IQR, 11-18]; 49 [25%] with prior neurosurgical resection), 83 (42%) completed the 6-month assessment. For the primary outcome, between baseline and postbaseline assessments through the 6-month follow-up, stereotactic radiation changed the weighted composite MD Anderson Symptom Inventory-Brain Tumor score from 2.69 to 2.37 (mean change, -0.32) and hippocampal-avoidance whole brain radiation changed the score from 2.29 to 3.03 (mean change, 0.74) (mean difference, -1.06 [95% CI, -1.54 to -0.58]; P < .001). Related grade 3-5 adverse events occurred in 12 patients (12%) in the stereotactic radiation group and 13 patients (13%) in the hippocampal-avoidance whole brain radiation group; grade 1-3 fatigue was most frequent (27 [28%] vs 43 [44%], respectively). CONCLUSIONS AND RELEVANCE: In patients with 5 to 20 brain metastases, these findings support stereotactic radiation over hippocampal-avoidance whole brain radiation to improve symptoms and interference with daily functioning, key components of quality of life. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03075072.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Aizer AA, Shin KY, Catalano PJ, et al. Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial. JAMA. 2026. PMID: 41712219. doi:10.1001/jama.2026.0076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。